First-in-human Phase 1 clinical trial of RIPK1 inhibitor in healthy volunteers.
Phase of Trial: Phase I
Latest Information Update: 26 Mar 2018
At a glance
- Drugs DNL-747 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; First in man
- 26 Mar 2018 New trial record
- 19 Mar 2018 According to Denali Therapeutics Inc media release, first patient has been dosed.